TNFRSF17 and Miyoshi myopathy: Herein, this review provides an update on the most recent clinical trials and their relevant preclinical findings in novel cellular immunotherapeutic strategies against MM, especially ADCs, bi-specific or tri-specific T cell engagers or antibodies, autologous CAR-T cells, and allogenic CAR-NK cells, targeting BCMA or other novel targets and future perspectives.